BG102041A - Оксидирани хетероцикли съдържащи сулфонамидни инхибитори на аспартил протеазата - Google Patents

Оксидирани хетероцикли съдържащи сулфонамидни инхибитори на аспартил протеазата

Info

Publication number
BG102041A
BG102041A BG102041A BG10204197A BG102041A BG 102041 A BG102041 A BG 102041A BG 102041 A BG102041 A BG 102041A BG 10204197 A BG10204197 A BG 10204197A BG 102041 A BG102041 A BG 102041A
Authority
BG
Bulgaria
Prior art keywords
aspartylprotease
inhibitors
oxidized
hiv
heterocycles containing
Prior art date
Application number
BG102041A
Other languages
English (en)
Inventor
Roger Tung
Govinda BHISETTI
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of BG102041A publication Critical patent/BG102041A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Изобретението се отнася до нов клас сулфонамиди, които са аспартилпротеазни инхибитори, и до фармацевтични състави, съдържащи тези съединения. Те са особено подходящи за инхибиране на HIV-1 и HIV-2 протеазната активност и могат успешно да се използват като противовирусни средства срещу HIV-1 и HIV-2 вируси. Изобретението се отнася също и до методиза инхибиране активността на HIV аспартилпротеазата, при които се прилагат тези съединения.
BG102041A 1995-04-19 1997-11-13 Оксидирани хетероцикли съдържащи сулфонамидни инхибитори на аспартил протеазата BG102041A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/424,810 US5691372A (en) 1995-04-19 1995-04-19 Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
PCT/US1996/005473 WO1996033187A1 (en) 1995-04-19 1996-04-18 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Publications (1)

Publication Number Publication Date
BG102041A true BG102041A (bg) 1998-09-30

Family

ID=23683966

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102041A BG102041A (bg) 1995-04-19 1997-11-13 Оксидирани хетероцикли съдържащи сулфонамидни инхибитори на аспартил протеазата

Country Status (34)

Country Link
US (2) US5691372A (bg)
EP (3) EP1637528B1 (bg)
JP (1) JP4240532B2 (bg)
KR (1) KR100485237B1 (bg)
CN (1) CN1110491C (bg)
AP (2) AP9600827A0 (bg)
AR (1) AR004663A1 (bg)
AT (3) ATE479674T1 (bg)
AU (1) AU712913B2 (bg)
BG (1) BG102041A (bg)
BR (1) BR9608033A (bg)
CA (1) CA2217745C (bg)
CO (1) CO4700433A1 (bg)
CZ (1) CZ329497A3 (bg)
DE (3) DE69638252D1 (bg)
DK (1) DK0833826T3 (bg)
EA (1) EA000906B1 (bg)
EE (1) EE9700254A (bg)
ES (3) ES2351970T3 (bg)
GE (1) GEP20001915B (bg)
HU (1) HUP9801948A3 (bg)
IL (1) IL117962A0 (bg)
IS (1) IS4575A (bg)
MY (1) MY115797A (bg)
NO (1) NO974744L (bg)
NZ (1) NZ307342A (bg)
PE (1) PE43697A1 (bg)
PL (1) PL322904A1 (bg)
PT (1) PT833826E (bg)
SK (1) SK143097A3 (bg)
TR (1) TR199701194T1 (bg)
TW (1) TW404945B (bg)
WO (1) WO1996033187A1 (bg)
ZA (1) ZA962891B (bg)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JP3657002B2 (ja) 1992-08-25 2005-06-08 ジー．ディー．サール アンド カンパニー レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
NZ335480A (en) 1996-12-31 2001-04-27 Guilford Pharm Inc Neurotrophic low molecular weight N-linked sulfonamides of heterocyclic thioesters and their use as inhibitors of immunophilin proteins
EP1019056A1 (en) * 1997-05-17 2000-07-19 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
BR9814484A (pt) * 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
NZ508855A (en) * 1998-06-19 2003-10-31 Vertex Pharma Sulfonamide inhibitors of HIV aspartyl protease
JP4776775B2 (ja) * 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
TWI260322B (en) 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
EP1159278B1 (en) * 1999-02-12 2005-11-30 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
WO2001025240A1 (en) * 1999-10-06 2001-04-12 Tibotec Pharmaceuticals Ltd. HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR
BR0109602A (pt) 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
OA12464A (en) * 2001-04-09 2006-05-24 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors.
US20040009890A1 (en) * 2002-01-07 2004-01-15 Erickson John W. Broad spectrum inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003300375A1 (en) * 2002-10-11 2004-05-04 Semplastics, L.L.C. Retaining ring for use on a carrier of a polishing apparatus
JP2006508166A (ja) * 2002-11-27 2006-03-09 イーラン ファーマスーティカルズ、インコーポレイテッド 置換尿素及びカルバメート
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2008533017A (ja) * 2005-03-11 2008-08-21 スミスクライン ビーチャム コーポレーション Ｈｉｖプロテアーゼ阻害薬
JP2007202679A (ja) * 2006-01-31 2007-08-16 Juki Corp ミシンの糸調子装置
JP2007202833A (ja) * 2006-02-02 2007-08-16 Juki Corp ミシンの糸調子装置
EP2120562A4 (en) * 2006-11-21 2010-01-13 Purdue Research Foundation METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS
WO2009091941A1 (en) 2008-01-17 2009-07-23 Purdue Research Foundation Small molecule inhibitors of hiv proteases
EP2307345A4 (en) 2008-07-01 2012-05-02 Purdue Research Foundation NON-PEPTIDINHIBITORS OF HIV-1 PROTEASE
EP2304043A4 (en) 2008-07-09 2012-05-30 Purdue Research Foundation HIV PROTEASE INHIBITORS AND METHOD FOR THEIR USE
CN105272991B (zh) * 2014-06-26 2017-11-07 成都中医药大学 一种化合物晶型
US11090030B2 (en) 2016-11-10 2021-08-17 Leltek Inc. Ultrasound apparatus and ultrasound emission method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) * 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) * 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) * 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) * 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) * 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) * 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
GB2200115B (en) * 1987-01-21 1990-11-14 Sandoz Ltd Novel peptide derivatives, their production and use
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) * 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007329A1 (en) * 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for pharmacologically active compounds
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0665215A1 (en) * 1990-06-01 1995-08-02 The Du Pont Merck Pharmaceutical Company 1,4-Diamino-2,3-dihydroxybutanes
TW225540B (bg) * 1990-06-28 1994-06-21 Shionogi & Co
DK0558673T3 (da) * 1990-11-19 1996-07-29 Monsanto Co Retrovirale proteaseinhibitorer
ATE296624T1 (de) * 1990-11-19 2005-06-15 Monsanto Co Retrovirusprotease inhibitoren
EP0731088B1 (en) * 1990-11-19 2000-10-04 Monsanto Company Retroviral protease inhibitors
EP0554400B1 (en) * 1990-11-19 1997-07-23 Monsanto Company Retroviral protease inhibitors
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
CA2081970C (en) * 1991-11-08 1997-07-08 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
AU4253193A (en) * 1992-05-20 1993-12-13 G.D. Searle & Co. Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
JPH07508020A (ja) * 1992-05-21 1995-09-07 ジー．ディー．サール　アンド　カンパニー レトロウイルスプロテアーゼインヒビター
JP3657002B2 (ja) * 1992-08-25 2005-06-08 ジー．ディー．サール アンド カンパニー レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
US5521219A (en) * 1992-08-25 1996-05-28 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ATE154800T1 (de) * 1992-08-25 1997-07-15 Searle & Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US6156768A (en) * 1992-10-30 2000-12-05 G. D. Searle & Co. Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
DK0666843T3 (da) * 1992-10-30 2000-03-20 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfaminsyrer, der kan anvendes som inhibitorer af retrovirale proteaser
WO1994018192A1 (en) * 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (bg) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
AU7669794A (en) * 1993-08-24 1995-03-21 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій

Also Published As

Publication number Publication date
HK1009811A1 (en) 1999-06-11
CZ329497A3 (cs) 1998-03-18
KR19990007823A (ko) 1999-01-25
WO1996033187A1 (en) 1996-10-24
AP9701104A0 (en) 1997-10-31
ES2351970T3 (es) 2011-02-14
AU712913B2 (en) 1999-11-18
TR199701194T1 (xx) 1998-03-21
EP1637528A1 (en) 2006-03-22
DK0833826T3 (da) 2002-05-06
AP9600827A0 (en) 1997-10-17
EP1136479B1 (en) 2005-12-28
PE43697A1 (es) 1997-10-11
IS4575A (is) 1997-10-02
NZ307342A (en) 1999-04-29
MY115797A (en) 2003-09-30
KR100485237B1 (ko) 2005-09-30
AR004663A1 (es) 1999-03-10
EA199700330A1 (ru) 1998-04-30
IL117962A0 (en) 1996-08-04
PT833826E (pt) 2002-06-28
CO4700433A1 (es) 1998-12-29
CN1110491C (zh) 2003-06-04
EE9700254A (et) 1998-04-15
SK143097A3 (en) 1998-03-04
HUP9801948A3 (en) 2002-04-29
ZA962891B (en) 1996-10-15
HUP9801948A2 (hu) 1999-09-28
EP0833826B1 (en) 2002-01-23
ATE479674T1 (de) 2010-09-15
PL322904A1 (en) 1998-03-02
EP1136479A1 (en) 2001-09-26
ES2171670T3 (es) 2002-09-16
NO974744D0 (no) 1997-10-14
AU5665596A (en) 1996-11-07
EA000906B1 (ru) 2000-06-26
BR9608033A (pt) 1999-01-12
DE69618779D1 (de) 2002-03-14
AP862A (en) 2000-08-04
CA2217745A1 (en) 1996-10-24
DE69638252D1 (de) 2010-10-14
NO974744L (no) 1997-10-14
EP0833826A1 (en) 1998-04-08
JP4240532B2 (ja) 2009-03-18
HK1092791A1 (en) 2007-02-16
US5691372A (en) 1997-11-25
CN1184474A (zh) 1998-06-10
ATE314360T1 (de) 2006-01-15
DE69618779T2 (de) 2002-08-29
ATE212344T1 (de) 2002-02-15
DE69635679T2 (de) 2006-08-31
DE69635679D1 (de) 2006-02-02
EP1637528B1 (en) 2010-09-01
GEP20001915B (en) 2000-01-05
US5990155A (en) 1999-11-23
CA2217745C (en) 2011-07-05
TW404945B (en) 2000-09-11
ES2256117T3 (es) 2006-07-16
JPH11504628A (ja) 1999-04-27

Similar Documents

Publication Publication Date Title
BG102048A (bg) Тетрахидрофурансъдържащи сулфонамиди като инхибитори на аспартилпротеаза
AP9600827A0 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease.
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
GR3024181T3 (en) N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors.
GR3029378T3 (en) Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
RU95109928A (ru) Сульфонамидные ингибиторы hiy-аспартил-протеазы, фармацевтическая композиция, способ лечения, способ идентификации ингибитора
CA2210889A1 (en) Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
KR950702960A (ko) 레트로바이러스 프로테아제 저해제로서 유용한 히드록시에틸아미노 술폰아미드(hydroxyethylamino sulfonamides useful as retroviral protease inhibitors)
WO1999065870A3 (en) Sulfonamide inhibitors of aspartyl protease
CA2140928A1 (en) Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
CA2096407A1 (en) Retroviral protease inhibitors
AU5736494A (en) Cyclic sulfone containing retroviral protease inhibitors
CA2096409A1 (en) Retroviral protease inhibitors
MY119031A (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
MY137777A (en) Inhibitors of aspartyl protease
NZ303861A (en) Amino acid hydroxyethylamine sulphonamide derivatives as protease inhibitors
CA2215066A1 (en) Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
ES2059289T1 (es) Inhibidores de la proteasa retrovirica.
EP1637518A3 (en) Inhibitors of aspartyl protease
AU4765396A (en) Method of preparing retroviral protease inhibitor intermediates
GR3023044T3 (en) Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors.
MX9708057A (es) Sulfonamidas que contienen thf inhibidoras de la aspartilproteasa.
SU661039A1 (ru) Сталь
ES8609253A1 (es) Un procedimiento para la preparacion de derivados de dihi- dropiridina
CA2155129A1 (en) Combinations of Retroviral Inhibitors